Activation of farnesoid X receptor (FXR) markedly attenuates development of atherosclerosis in animal models. However, the underlying mechanism is not well elucidated. Here, we show that the FXR agonist, obeticholic acid (OCA), increases fecal cholesterol excretion and macrophage reverse cholesterol transport (RCT) dependent on activation of hepatic FXR. OCA does not increase biliary cholesterol secretion, but inhibits intestinal cholesterol absorption. OCA markedly inhibits hepatic cholesterol 7a-hydroxylase (Cyp7a1) and sterol 12a-hydroxylase (Cyp8b1) partly through inducing small heterodimer partner, leading to reduced bile acid pool size and altered bile acid composition, with the a/b-muricholic acid proportion in bile increased by 2.6-fold and taurocholic acid (TCA) level reduced by 71%. Overexpression of Cyp8b1 or concurrent overexpression of Cyp7a1 and Cyp8b1 normalizes TCA level, bile acid composition, and intestinal cholesterol absorption. Conclusion: Activation of FXR inhibits intestinal cholesterol absorption by modulation of bile acid pool size and composition, thus leading to increased RCT. Targeting hepatic FXR and/or bile acids may be useful for boosting RCT and preventing the development of atherosclerosis. (HEPATOLOGY 2016;64:1072-1085 T he farnesoid X receptor (FXR) is a nuclear hormone receptor that regulates multiple biological processes. FXR plays an important role in regulating bile acid, lipid and glucose metabolism, inflammation, and energy homeostasis.
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(1-3) Activation of FXR improves insulin sensitivity, lowers blood and hepatic triglycerides (TGs) and blood cholesterol, and inhibits hepatic inflammatory response. (4) (5) (6) (7) In addition, activation of FXR increases macrophage reverse cholesterol transport (RCT), (8) a process that delivers cholesterol from peripheral macrophages to the liver for secretion to the bile and feces. Macrophage RCT is known to be atheroprotective. (9, 10) Consistent with the role of FXR in RCT and TG metabolism, activation of FXR is shown to protect against development of atherosclerosis (11, 12) and nonalcoholic fatty liver disease (NAFLD). (13) Given all these beneficial effects, FXR has been considered an attractive therapeutic target for treatment of metabolic disorders. (14, 15) FXR is highly expressed in the liver, intestine, kidney, and adrenal gland, but is undetectable in macrophages. (16) Thus, activation of FXR affects the Abbreviations: Abcg5, ATP-binding cassette subgroup G member 5; Abcg8, ATP-binding cassette subgroup G member 8; acLDL, acetylated low-density lipoprotein; Bsep, bile salt export protein; CA, cholic acid; cDNA, complementary DNA; cpm, counts per minute; Cyp7a1, cholesterol 7a-hydroxylase; Cyp8b1, sterol 12a-hydroxylase; DCA, deoxycholic acid; DMEM, Dulbecco's modified Eagle's medium; EMEM, Eagle's minimum essential medium; FBS, fetal bovine serum; FPLC, fast protein liquid chromatography; FXR, farnesoid X receptor; HDL, high-density lipoprotein; HDL-C, HDL-cholesterol; LDL, low-density lipoprotein; LSC, liquid scintillation counter; MCAs, muricholic acids; a/b-MCA, a/b-muricholic acid; Mdr2, multidrug resistance protein 2; mRNA, messenger RNA; NAFLD, nonalcoholic fatty liver disease; OCA, obeticholic acid; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; RCT, reverse cholesterol transport; Shp, small heterodimer partner; SR-BI, scavenger receptor group B type 1; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; TGs, triglycerides; TUDCA, tauroursodeoxycholic acid. development of atherosclerosis likely through modulating plasma lipid levels. We have previously shown that activation of FXR lowers plasma high-density lipoprotein (HDL) level by inducing scavenger receptor group B type 1 (SR-BI). (8) Overexpression of SR-BI is shown to lower plasma HDL-cholesterol (HDL-C) level, promote RCT, and protect against atherosclerosis. (17, 18) Consequently, activation of FXR also increases macrophage RCT. (8) So far, the mechanism underlying FXRinduced of RCT is not well elucidated.
Cholesterol absorption is an important component of RCT. Around 50% dietary or biliary cholesterol is absorbed in the intestine. Therefore, inhibition of intestinal cholesterol absorption promotes RCT. (19) (20) (21) As amphipathic molecules, bile acids are important regulators of cholesterol absorption. Among all the bile acids, cholic acid (CA) has the most capability to promote cholesterol absorption, whereas muricholic acids (MCAs) are the strongest inhibitors of cholesterol absorption. (22) FXR plays an essential role in all aspects of bile acid metabolism, including bile acid synthesis, conjugation, secretion, absorption, and uptake by hepatocytes. (23) Classic bile acid synthesis is controlled mainly by two rate-limiting enzymes, cholesterol 7a-hydroxylase (CYP7A1) and sterol 12a-hydroxylase (CYP8B1), which are inhibited by FXR. CYP8B1 determines the production rate of CA.
In this study, we used global and tissue-specific Fxr 2/2 mice to investigate how FXR regulates RCT. Our data show that the FXR agonist, obeticholic acid (OCA), increases fecal cholesterol excretion and macrophage RCT through activation of hepatic FXR. Such an effect coincides with unchanged biliary cholesterol secretion. Activation of FXR inhibits intestinal cholesterol absorption by altering bile acid pool size and composition, and this effect is abolished by overexpression of CYP8B1 or CYP7A1 plus CYP8B1. These data demonstrate that activation of FXR increases RCT by regulating bile acid synthesis and composition and subsequent inhibition of intestinal cholesterol absorption.
Materials and Methods

MICE, FXR LIGANDS, AND ADENOVIRUSES
C57BL/6 mice, Fxr 2/2 mice, albumin-Cre mice, and vilin-Cre were purchased from The Jackson Laboratory (Bar Harbor, ME). Fxr fl/fl mice (24) and Shp 2/2 mice (25) have been described previously. Liver-or intestine-specific Fxr 2/2 mice were generated by crossing albumin-Cre mice or vilin-Cre mice with Fxr fl/fl mice. Where indicated, 10-to 12-week-old mice were gavaged with either vehicle (0.5% carboxymethycellulose; Sigma-Aldrich, St. Louis, MO) or vehicle containing GW4064 (30 mg/kg, twice a day) or OCA (40 mg/kg) for 6-9 days. Adenoviruses expressing rat Cyp7a1 (Ad-rCyp7a1), (26) mouse Cyp8b1 (Ad-mCyp8b1), (27) FXRa1-VP16, and FXRa2-VP16 (4) have been described. Unless otherwise stated, mice were euthanized 7 days postinjection. In general, all mice were fasted for 5-6 hours before euthanization. All animal experiments were approved by the institutional animal care and use committee at Northeast Ohio Medical University (Rootstown, OH).
CHEMICAL REAGENTS AND ANTIBODIES
Applied Biosystems (Foster City, CA). CYP7A1 antibody was a general gift from Dr. David Russel at University of Texas Southwestern Medical Center. CYP8B1 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Calnexin and bactin were purchased from Novus Biologicals (Littleton, CO).
REAL-TIME POLYMERASE CHAIN REACTION
RNA was isolated using TRIzol Reagent. Messenger RNA (mRNA) levels were determined by quantitative reverse-transcription polymerase chain reaction (PCR) on a 7500 real-time PCR machine from Applied Biosystems (Foster City, CA) by using SYBR Green Supermix (Roche, Indianapolis, IN). Results were calculated using threshold cycle values and normalized to 36B4 mRNA level.
WESTERN BLOTTING ASSAYS
Western blotting assays were performed using whole-liver lysates (4) or nuclear extracts of the liver samples, (28, 29) as described. Gel band intensity was quantified using ImageJ software (National Institutes of Health, Bethesda, MD) and normalized to b-actin or histone.
LIPID AND LIPOPROTEIN ANALYSIS
Approximately 100 mg of liver tissue were homogenized in methanol and lipids were extracted in chloroform/methanol (2:1, v/v), as described. (30) Hepatic TG and cholesterol levels were then quantified using Infinity reagents from Thermo Scientific (Waltham, MA). Plasma TG and cholesterol levels were also determined using Infinity reagents. Fast protein liquid chromatography (FPLC) analysis of lipoprotein profile was performed as described. (29, 31) 
BILE ACID LEVEL AND COMPOSITION
Bile acids in liver, intestine, and gallbladder were extracted using ethanol. Bile acid levels in liver, intestine, gallbladder or plasma were measured using a bile acid kit (Diazyme, San Diego, CA). Total bile acids in liver, intestine, and gallbladder were used for calculation of total bile acids/bile acid pool size. Individual bile acids were quantified on a Waters Acquity HClass UPLC system using a Waters Acquity BEH C18 column (2.1 3 100 mm) coupled to a Waters Xevo G2 QTOFMS, as described. (32) 
GALLBLADDER CANNULATION
Mice were fasted for 4 hours followed by anesthesia. The lower end of the common bile duct was ligated and the gallbladder cannulated below the entrance of the cystic duct using a PE-10 catheter (Becton Dicksinson, Sparks, MD). After successful catheterization and flow of fistula bile, the cystic duct was doubly ligated. Hepatic bile was collected by gravity for the first 1-2 hours.
IN VIVO RCT
The in vivo RCT was performed essentially as described. (8, 33) Briefly, J774 macrophages (ATCC, Manassas, VA), grown in suspension in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and penicillin/streptomycin, were cultured in uncoated cell-culture dishes. To load cells with 3 H-cholesterol and acetylated low-density lipoprotein (acLDL), J774 cells were incubated in DMEM/10% FBS containing 5 lCi/mL of 3 H-cholesterol and 25 lg/mL of acLDL for 48 hours, followed by wash in phosphate-buffered saline (PBS) and equilibration for 4 hours in DMEM supplemented with 0.2% bovine serum albumin and penicillin/streptomycin. Before injection, cells were pelleted and resuspended in Eagle's minimum essential medium (EMEM; ATCC). All mice were caged individually with free access to water and food. Mice were injected intraperitoneally with 0.5 mL of J774 cells (typically 5 3 10 6 cells) in EMEM containing 6.5-10 3 10 6 counts per minute (cpm). Blood was collected at 24 and 48 hours, and plasma 3 H-tracers were assayed using a liquid scintillation counter (LSC). Feces were collected continuously from 0 to 48 hours. At the end of the experiment, mice were perfused with cold PBS. A portion of the liver was removed for lipid and RNA extraction.
Approximately 100 mg of liver were homogenized in methanol and lipids were extracted in chloroform/ methanol (2:1, v/v), as described. (30) Lipids were collected, dried, and resuspended in toluene and counted in an LSC.
FECAL CHOLESTEROL AND BILE ACIDS
Fecal total sterols, cholesterol, and bile acids were extracted as described. (8, 33) Radioactivity was measured using an LSC. For mice that were not given any radioisotopes, feces were collected consecutively for 48 hours. After total sterols, cholesterol, and bile acids were extracted, free cholesterol and total bile acids were measured using a free cholesterol kit (Wako USA, Richmond, VA) or total bile acid kit (Diazyme).
INTESTINAL CHOLESTEROL ABSORPTION
Intestinal cholesterol absorption was performed as described. (8, 34) Briefly, mice were injected with 2.5 lCi of 3 H-cholesterol in Intralipid (Sigma-Aldrich) by tail vein injection, followed by immediate gavage with 1 lCi of 
STATISTICAL ANALYSIS
Statistical significance was analyzed using an unpaired Student t test or analysis of variance (GraphPad Prism; GraphPad Software Inc., La Jolla CA). All values are expressed as mean 6 standard error of the mean. Differences were considered statistically significant at P < 0.05. (Fig. 1C) and increased fecal free cholesterol level (Fig. 1D , left panel) in control mice, but not in L-Fxr 2/2 mice. In addition, OCA reduced fecal bile acid levels in both genotypes (Fig. 1D, right  panel) .
Results
OCA LOWERS PLASMA CHOLESTEROL AND INCREASES FECAL CHOLESTEROL EXCRETION THROUGH ACTIVATION OF HEPATIC FXR
In contrast to what was observed in L-Fxr 2/2 mice, OCA reduced plasma cholesterol and increased fecal free cholesterol level in both control mice and I-Fxr (Fig. 1E,F , left panel), but reduced fecal bile acid level only in control mice (Fig. 1F, right panel) . Collectively, the data of Fig. 1 indicate that OCA reduces plasma cholesterol and increases fecal cholesterol level through activation of hepatic FXR, whereas reduction in fecal bile acids is dependent on activation of intestinal FXR.
OCA INHIBITS CYP7A1 AND CYP8B1 EXPRESSION THROUGH ACTIVATION OF HEPATIC AND/ OR INTESTINAL FXR AND PARTLY THROUGH SMALL HETERODIMER PARTNER
To determine whether OCA functioned properly in animals, we analyzed hepatic gene expression. As expected, OCA induced Shp (small heterodimer partner), a well-characterized FXR target gene, and repressed Cyp7a1 and Cyp8b1 mRNA levels in wildtype mice, but not in Fxr 2/2 mice ( Fig. 2A) . However, repression of Cyp7a1 or Cyp8b1 was mitigated or abolished in L-Fxr 2/2 mice (Fig. 2B ) or I-Fxr 2/2 mice (Fig. 2C) , suggesting that OCA represses Cyp7a1 and Cyp8b1 expression through activation of hepatic and/ or intestinal FXR. Previous studies show that activation of FXR induces intestinal expression of FGF15, an enterohepatic hormone, to repress hepatic CYP7A1 and CYP8B1 expression. (35, 36) In I-Fxr 2/2 mice, OCA treatment completely failed to inhibit Cyp7a1 and only partially inhibited Cyp8b1 (Fig. 2C) , which may explain why OCA treatment reduces fecal bile acid levels dependent on activation of intestinal FXR (Fig. 1F) .
SHP is known to inhibit bile acid synthesis. (25, 37) To determine whether Shp is required for FXR to inhibit both Cyp7a1 and Cyp8b1, we gavaged wildtype mice and Shp 2/2 mice with vehicle or the specific FXR agonist, GW4064, for 7 days. The data of Fig.  2D show that GW4064 markedly reduced both Cyp7a1 and Cyp8b1 expression, and such a reduction was greatly attenuated in Shp 2/2 mice, indicating that activation of FXR represses Cyp7a1 and Cyp8b1 expression partly through induction of SHP. . Bile acid levels in liver, gallbladder, and intestine, as well as total bile acid levels, were determined. *P < 0.05; **P < 0.01. In (E), the difference was compared between the OCA-treated group and the vehicle-treated group of the same genotype.
Consistent with the involvement of both hepatic and intestinal FXR in regulating CYP7A1 and CYP8B1 expression, OCA treatment reduced bile acid levels in liver and gallbladder or intestine dependent on activation of hepatic or intestinal FXR, respectively (Fig. 2E) . In addition, both hepatic and intestinal FXR were required for OCA to reduce bile acid pool size (Fig. 2E) or plasma bile acid level (Supporting Fig. S1 ). OCA did not lower plasma bile acid levels in global Fxr 2/2 mice (data not shown). Together, the data of Fig. 2 demonstrate that suppression of CYP7A1 and CYP8B1 expression and bile acid pool size involves activation of hepatic and/or intestinal FXR and its downstream target, SHP.
HEPATIC FXR IS REQUIRED FOR OCA TO INCREASE MACROPHAGE RCT
The data of Fig. 1 suggest that OCA increases fecal free cholesterol excretion and lowers plasma cholesterol level through activation of hepatic FXR. Analysis of plasma lipoprotein profile by FPLC indicates that OCA lowered plasma cholesterol levels in control littermates primarily by reducing HDL-C (Fig. 3A) . In addition, there was an increase in low-density lipoprotein (LDL)-cholesterol in L-Fxr 2/2 mice (Fig. 3A) . Given that HDL plays an important role in RCT, we determined the role of hepatic FXR in macrophage RCT.
Forty-eight hours after injection of J774 macrophages loaded with [ 3 H]cholesterol and acLDL, blood radioactivity was significantly reduced (Fig. 3B) (Fig. 3F) , but induced SR-BI mRNA and protein levels (Supporting Fig. S2 ), indicating that OCA functioned properly in vivo. Thus, the data of Fig. 3 demonstrate that hepatic FXR activation is required for OCA to increase macrophage RCT.
ACTIVATION OF FXR DOES NOT INCREASE BILIARY CHOLESTEROL SECRETION
Biliary cholesterol secretion plays an important role in RCT. Given that hepatic FXR activation is required for OCA-induced macrophage RCT, we investigated whether activation of FXR increased biliary cholesterol secretion. FXR has four isoforms. Previous data suggest that FXRa1 and FXRa2 may have similar functions as FXRa3 and FXRa4, respectively. (16) Therefore, we over-expressed FXRa1-VP16 or FXRa2-VP16 in the liver to constitutively activate FXRa1 or FXRa2. As expected, activation of FXRa1 or FXRa2 markedly inhibited bile acid secretion (Fig.  4A, left panel) . However, activation of FXRa2, but not FXRa1, inhibited bile flow (Fig. 4A , middle panel) and reduced biliary cholesterol secretion (Fig. 4A , right panel). Consistent with these observations, activation of FXRa1 or FXRa2 markedly inhibited Cyp7a1 and Cyp8b1 expression (Fig. 4B) . Interestingly, activation of FXRa1 induced bile salt export protein (Bsep) by 9-fold, whereas activation of FXRa2 induced Bsep only by 2.3-fold (Fig. 4B) . In addition, activation of FXRa1, but not FXRa2, induced multidrug resistance protein 2 (Mdr2) and ATP-binding cassette subgroup G member 5 (Abcg5) expression (Fig. 4B) . Neither FXRa1 nor FXRa2 activation had an effect on ATPbinding cassette subgroup G member 8 (Abcg8) expression (Fig. 4B) .
We next investigated whether the specific FXR agonist, GW4064, had similar effects as constitutively activated FXR (FXR-VP16) in the liver. Treatment of mice with GW4064 had no effect on bile flow (Fig.  4C ) or biliary cholesterol secretion (Fig. 4D) . In a macrophage RCT study, we did not observe any change in biliary [ 3 H] radioactivity after GW4064 treatment (Fig. 4E) . In addition, GW4064 treatment significantly induced Shp and Bsep, but inhibited Cyp7a1 and Cyp8b1 (Fig. 4F) , suggesting that GW4064 functioned properly in vivo.
Studies with another specific FXR agonist, OCA, produced similar results. OCA treatment reduced bile acid secretion in wild-type, but not in Fxr 2/2 , mice (Supporting Fig. S3A) , and had no effect on bile flow (Supporting Fig. S3B ) or biliary cholesterol secretion (Supporting Fig. S3C ) in wild-type or Fxr 2/2 mice. Further studies involving liver-or intestine-specific Fxr 2/2 mice show that OCA inhibited biliary bile acid secretion dependent on activation of both hepatic and intestinal FXR (Supporting Fig. S3D ). OCA treatment had no effect on bile flow in Fxr fl/fl mice, LFxr 2/2 mice, or I-Fxr 2/2 mice (Supporting Fig.  S3E) . Together, the data of Fig. 4 and Supporting Fig.  S3 demonstrate that activation of FXR does not increase biliary cholesterol secretion and inhibits bile acid secretion through activation of both hepatic and intestinal FXR.
ACTIVATION OF FXR REDUCES INTESTINAL CHOLESTEROL ABSORPTION PRIMARILY THROUGH INHIBITION OF HEPATIC CYP8B1
Intestinal cholesterol absorption plays an important role in cholesterol homeostasis and is an important component of RCT. Bile acids play a critical role in regulating cholesterol absorption, with CA being the most efficient bile acid in promoting cholesterol absorption. In the classic pathway of bile acid biosynthesis, CYP7A1 catalyzes the rate-limiting step, whereas CYP8B1 determines rate of CA biosynthesis (Fig. 5A) . OCA treatment significantly inhibited cholesterol absorption (Fig. 5B) . This inhibition was attributed to activation of hepatic FXR because OCA was able to inhibit intestinal cholesterol absorption in I-Fxr 2/2 mice, but not in L-Fxr 2/2 mice (Supporting Fig. S4 ). Given that FXR activation markedly inhibited both Cyp7a1 and Cyp8b1 expression, we asked whether recapitulation of hepatic Cyp7a1 and/or Cyp8b1 levels would prevent FXR-induced inhibition of cholesterol absorption. Overexpression of Cyp7a1 , and hepatic mRNA levels (F) were determined. *P < 0.05; **P < 0.01. Unless otherwise indicated, the difference is shown when compared to vehicle-treated control mice. Abbreviation: VLDL, very-low-density lipoprotein.
(from rat complementary DNA [cDNA]) and/or Cyp8b1 (from mouse cDNA) had no effect on intestinal cholesterol absorption in vehicle-treated mice (Supporting Fig. S5A-D) . Concurrent expression of Cyp7a1 and Cyp8b1 or overexpression of Cyp8b1 alone, but not Cyp7a1 alone, recovered intestinal cholesterol absorption to the normal level in OCA-treated mice (Fig. 5B) . OCA markedly inhibited endogenous Cyp7a1 mRNA level (Fig. 5C) , and reexpression of Cyp7a1 was able to recapitulate hepatic CYP7A1 protein level to the normal level (Fig. 5D ). The data of Fig. 5D ,E show that OCA markedly inhibited hepatic levels of Cyp8b1 mRNA and protein, which were reversed by Cyp8b1 overexpression. Taken together, 
OVEREXPRESSION OF CYP8B1 OR CYP7A1 PLUS CYP8B1 PREVENTS FXR-INDUCED INCREASE IN MURICHOLIC ACID LEVEL AND DECREASE IN TAUROCHOLIC ACID LEVEL
To determine how overexpression of CYP7A1 and CYP8B1 prevents FXR-induced inhibition of intestinal cholesterol absorption, we analyzed bile acid pool size and bile acid composition. As expected, overexpression of Cyp7a1 and/or Cyp8b1 increased bile acid levels in the intestine, liver, and/or gallbladder, as well as total bile acid levels, in vehicle-treated mice (Supporting Fig. S6A-D) . Activation of FXR by OCA significantly reduced (Fig. 6A,B ) or tended to (Fig. 6C ) reduce bile acid level in the intestine (Fig.  6A), liver (Fig. 6B), and gallbladder (Fig. 6C) . As a result, OCA significantly reduced bile acid pool size by 76% (Fig. 6D) . Overexpression of Cyp7a1 alone in OCA-treated mice partly or completely recovered bile acid levels in the intestine (Fig. 6A), liver (Fig. 6B) , and gallbladder (Fig. 6C ) and partly recovered total bile acid levels (Fig. 6D) . In contrast, concurrent expression of both Cyp7a1 and Cyp8b1 or Cyp8b1 overexpression alone completely recovered or increased bile acid levels in the intestine, liver, and gall bladder as well as total bile acid levels in OCA- ]cholesterol and intestinal cholesterol absorption was performed using the dual-isotope plasma ratio method (B). Hepatic Cyp7a1 mRNA level (C), protein levels (D), and Cyp8b1 mRNA level (E) were determined. *P < 0.05; **P < 0.01. Unless otherwise indicated, the difference is shown when compared to the vehicle treatment group. Abbreviation: ND, not detectable. treated mice (Fig. 6A-D) . Interestingly, although overexpression of Cyp7a1 or Cyp8b1 increased intestinal bile acid levels to a similar extent in OCA-treated mice (Fig. 6A) , Cyp8b1, but not Cyp7a1, overexpression was able to normalize cholesterol absorption (Fig. 5B) . FIG. 6 . Reexpression of CYP8B1 alone or CYP7A1 plus CYP8B1 prevents OCA from altering TCA and MCA levels. (A-F) C57BL/6 mice were injected intravenously with a control virus, Ad-rCyp7a1 and/or Ad-mCyp8b1. One day later, mice were gavaged with either vehicle or OCA (n 5 6). Bile acid levels in the intestine (A), liver (B), and gallbladder (C), as well as total bile acid levels (including intestine, liver, and gallbladder) (D), were analyzed. Individual bile acid levels in bile were quantified (E), and the composition (%) of individual bile acids under different treatments is shown (F). *P < 0.05; **P < 0.01. Unless otherwise indicated, the difference is shown when compared to the vehicle treatment group.
Analysis of individual bile acid levels in bile indicated that OCA treatment reduced, by 71%, levels of taurocholic acid (TCA), the most abundant bile acid, whereas concurrent expression of both Cyp7a1 and Cyp8b1 or Cyp8b1 overexpression alone recapitulated TCA level to the normal level (Fig. 6E) . OCA treatment also significantly reduced deoxycholic acid (DCA) and taurodeoxycholic acid (TDCA) levels, which could not be recovered to normal levels by Cyp8b1 or Cyp7a1 plus Cyp8b1 overexpression (Fig. 6E) . In contrast, OCA treatment had not much of an effect on the levels of CA, a/b-muricholic acid (a/b-MCA), taurochenodeoxycholic acid (TCDCA), or tauroursodeoxycholic acid (TUDCA; Fig. 6E ).
Further analysis of bile acid composition in bile indicated that OCA treatment increased relative levels of a/b-MCA from 11.3% to 29.4%, and this increase was blunted by overexpression of Cyp8b1 alone or Cyp7a1 plus Cyp8b1, but not by overexpression of Cyp7a1 alone (Fig. 6F) . Given that MCAs are the most hydrophilic bile acids and the most potent inhibitors of cholesterol absorption whereas cholic acids (CA and TCA) are the most potent promoters of cholesterol absorption among all the bile acids, (22) the data of Fig. 6 suggest that the changes in MCA and CA levels are responsible for the reduced cholesterol absorption after OCA treatment.
Discussion
Atherosclerosis is the leading cause of coronary heart disease. Activation of FXR has been shown to increase RCT (8) and protects against development of atherosclerosis in Ldlr 2/2 or Apoe 2/2 mice. (11, 12) In addition, activation of FXR also lowers TG levels and inhibits inflammation in the liver, thus preventing development of NAFLD. (13) Finally, activation of FXR improves insulin sensitivity in diabetic mice or humans. (4) (5) (6) These observations have suggested that FXR is a therapeutic target for treatment of common metabolic disorders, including NAFLD, atherosclerosis, and insulin resistance. However, the mechanism underlying the regulation of RCT by FXR is not well elucidated. By using tissue-specific Fxr 2/2 mice, herein we show that activation of FXR increases RCT by suppression of hepatic bile acid synthesis, alternation of bile acid composition, and subsequent inhibition of intestinal cholesterol absorption, a novel pathway that is independent of the canonical biliary secretion route.
Our previous data show that activation of FXR increases macrophage RCT through a pathway that requires SR-BI. (8) Given that FXR activation induces SR-BI expression in the liver, (8) one may speculate that FXR activation likely increases biliary cholesterol secretion. By using tissue-specific Fxr 2/2 mice, we show that the synthetic FXR agonist, OCA, increases macrophage RCT through activation of hepatic FXR. However, neither constitutive activation of FXR in the liver nor GW4064 or OCA treatment increases biliary cholesterol secretion. This latter observation supports the recent findings that the intestine is capable of modulating RCT directly. (38) In addition, our data show that FXR activation significantly inhibits biliary bile acid secretion. Given that FXR activation is known to increase phospholipid secretion, our observations raise that possibility that FXR activation may increase the formation of cholesterol gallstone.
The role of FXR in controlling bile acid homeostasis has been well established. Our data indicate that OCA represses both CYP7A1 and CYP8B1 expression through activation of hepatic and intestinal FXR and partly through inducing SHP. Overexpression of CYP8B1 or CYP7A1 plus CYP8B1 is sufficient to prevent OCA-induced inhibition of intestinal cholesterol absorption, demonstrating that activation of FXR inhibits intestinal cholesterol absorption by modulating bile acid metabolism. Gardes et al. have reported that synthetic FXR agonists, including OCA (also called 6E-CDCA), GW4064, R05186026, and X-Ceptor compound, all inhibit intestinal cholesterol absorption, reduce bile acid pool size, and decrease fecal bile acid excretion in Ldlr 2/2 mice that are fed a Western diet, (39) a known atherogentic mouse model. Thus, the studies by us and Gardes et al. indicate that activation of FXR inhibits intestinal cholesterol absorption in both wild-type (normal) mice and atherogenic mice by regulating bile acid metabolism. Activation of intestinal FXR has been shown to inhibit hepatic CYP7A1 expression through fibroblast growth factor 15/19. (35) However, recapitulation of hepatic CYP7A1 expression has no effect on FXR-induced inhibition of intestinal cholesterol absorption, supporting the finding that hepatic FXR activation is responsible for induction of RCT.
Hydrophobic bile acids, such as CA and DCA, promote cholesterol absorption whereas hydrophilic bile acids, such as MCAs, are potent inhibitors of cholesterol absorption. (22) In hamsters, TCA is identified as a potential plasma biomarker of early atheromatous plaque formation. (40) (44) Therefore, targeting bile acid synthesis may be a useful strategy for prevention of atherogenesis.
Accumulating data have indicated that FXR is an attractive target for treatment of diverse metabolic disorders, including atherosclerosis. The data presented here provide important insights into the mechanism underlying FXR-medicated inhibition of atherosclerosis. In addition, our studies suggest that FXR and bile acids may be targeted for enhancing RCT and thus for preventing the development of atherosclerosis.
